Avalyn Initiates Phase 2 Trial of Inhaled Nintedanib for Idiopathic Pulmonary Fibrosis
核心洞察
Avalyn (搜索) has dosed the first patient in the AURA Phase 2 clinical trial evaluating AP02, an inhaled formulation of nintedanib delivered via nebulization for idiopathic pulmonary fibrosis (搜索) treatment.
Phase 1 trials demonstrated that AP02 achieved higher lung exposure at lower doses compared to oral nintedanib while maintaining favorable safety profile with no reported diarrhea, cough, or bronchospasm.
The randomized, double-blind, placebo-controlled trial will enroll 160 treatment-naïve IPF patients to evaluate two dose levels of AP02 versus placebo over 12 weeks.
Avalyn (搜索), a clinical-stage biopharmaceutical company focused on inhaled therapies for rare respiratory diseases, has initiated dosing in the AURA Phase 2 clinical trial evaluating AP02, an inhaled formulation of nintedanib administered via nebulization, for patients with idiopathic pulmonary fibrosis (搜索) (IPF). The announcement marks a significant advancement in developing targeted lung delivery systems for antifibrotic therapies.
Novel Inhaled Delivery System Shows Promise
AP02 represents a novel formulation of nintedanib delivered using the PARI eFlow® nebulizer, specifically developed to optimize medication distribution to the distal lung. Phase 1 single- and multiple-ascending dose clinical trials in both healthy adult volunteers and IPF patients demonstrated favorable safety and tolerability at all evaluated dose levels.
The Phase 1 results revealed higher lung exposure following AP02 delivery relative to oral dosing while maintaining lower systemic exposures, highlighting the targeted delivery of nintedanib to the lung. Notably, AP02 demonstrated preferential lung exposure at substantially lower doses compared to oral administration.
"AURA builds on our robust Phase 1 program, where AP02 delivered via nebulization demonstrated preferential exposure in the lungs at substantially lower doses relative to oral administration, with a favorable safety profile including no cough or bronchospasm following repeat dosing," said Lyn Baranowski, Chief Executive Officer of Avalyn (搜索). "Importantly, there was no diarrhea reported, which is particularly notable given the profile of oral nintedanib."
Phase 2 Trial Design and Endpoints
The randomized, double-blind, placebo-controlled AURA Phase 2 clinical trial will evaluate the safety and efficacy of AP02 in patients with IPF. The study is expected to enroll 160 patients with IPF who are not currently on treatment and will evaluate two dose levels of AP02 compared to placebo.
The primary endpoint is the change from baseline in forced vital capacity (FVC) at Week 12. Key secondary and exploratory endpoints include time to disease progression, lung fibrosis scores based on quantitative high-resolution computed tomography (HRCT), and quality of life measurements.
Addressing Treatment Challenges
Joyce Lee, M.D., Professor of Medicine in Pulmonary Sciences and Critical Care Medicine and Director of the Interstitial Lung Disease Program at University of Colorado School of Medicine (搜索), who serves as a steering committee member for AP02, emphasized the potential clinical significance of the approach.
"For too long, many patients have struggled with the challenging side effects linked to standard-of-care oral medications and often discontinue treatment, despite the serious and progressive nature of the disease," Dr. Lee stated. "By delivering therapy directly to the lungs, AP02 has the potential to offer antifibrotic benefits with improved tolerability."
Comprehensive Pipeline Development
Beyond AP02, Avalyn (搜索) is advancing a comprehensive pipeline of inhaled antifibrotic therapies. The company's AP01 program, an optimized inhaled formulation of pirfenidone, is currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (搜索) (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial.
Avalyn (搜索) is also developing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver dual antifibrotic mechanisms through a single lung-targeted platform. The company aims to establish a new standard of care in pulmonary fibrosis (搜索) through inhaled, lung-targeted therapies by leveraging its proprietary drug-device approach and expertise in rare respiratory disease development.